NextRX

NextRX

Closed: Apr. 2018

About this raise

Who Should Be Interested:
Do you wish there was an easier way to check in at cannabis dispensaries? Wouldn’t it be great if there was a reward system for them too? If you said yes, then investing in NextRX Inc. could be for you. They’ve both streamlined the check in process at dispensaries and created a reward membership network, making your medical marijuana process a whole lot easier -- and rewarding!

The Company:
NextRX Inc. has created a network to streamline check-ins and reward patients who use Medical Marijuana (MMJ). Using the NextRX check-in system means that your registration is smooth, seamless, and secure, as well as HIPAA compliant. All you have to do is register with NextRX at a participating dispensary with your driver’s license and a valid MMJ Patient Recommendation. Then, just sign the dispensary’s user agreement, and you’ll receive an RX-Pass with your unique identification number that you can use to register and check-in at all other participating dispensaries. Plus, with NextRX, you earn reward points for your prescriptions. It’s like frequent flier miles -- but for pot. The rewards act as cash, and you can use them to purchase your medicine at any in-network dispensary. Dispensaries benefit by using the NextRX database to manage patient records, monitor inventory, keep track of patients’ purchases, and issue and redeem the loyalty reward points. So far, NextRX has built a network of about 16,000 patients through a few beta user dispensaries, and now they’re ready to expand and grow -- one dispensary and MMJ prescription at a time.

The Bottom Line:
With the MMJ market growing, and cannabis becoming legal in more places, having a network that offers easy check-ins and rewards will revolutionize the industry. NextRX is thinking ahead -- and they’re helping you with the rewards.

Expand

Investment Overview

Invested this round: $29,902

Deal Terms

Total Commitments ($USD)

Platform
Fundanna
Start Date
01/30/2018
Close Date
04/20/2018
Min. Goal
$20,000
Max Goal
$100,000
Min. Investment

$100

Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$5.00

Pre-Money Valuation

$4,000,000

Company & Team

Company

Year Founded
2015
Industry
Alcohol, Tobacco, & Recreational Drugs
Tech Sector
Location
Las Vegas, Nevada
Company Website
Visit Website

Team

Employees
2

Financials

Financials are not currently available for this company. This may occur if the company is still Testing the Waters, is a Regulation D offering, or if the financials are still under review and being confirmed by our team. For Reg CF and Reg A+ raises, please check back later.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
04/20/2018 Fundanna $4,000,000 $29,902 Equity - Common Funded RegCF
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
NextRX on Fundanna
Platform: Fundanna
Security Type: Equity - Common
Valuation: $4,000,000
Price per Share: $5.00

Follow company

Follow NextRX on Fundanna

Buy NextRX's Deal Report

Warning: according to the close date for this deal, NextRX may no longer be accepting investments.

NextRX Deal Report

Get Kingscrowd's comprehensive report on NextRX including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether NextRX is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the NextRX deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge